Kedudukan dalam Saham
#18693
Axcella Health Inc. is a U.S.-based clinical-stage biotechnology firm focused... Axcella Health Inc. is a U.S.-based clinical-stage biotechnology firm focused on developing novel therapeutic compositions derived from endogenous metabolic modulators. These aim to address complex diseases and improve overall health. The company's primary drug candidates are AXA1665 and AXA1125. AXA1665 is currently undergoing Phase 2 clinical trials, where it is being evaluated for its potential to lower the risk of recurrent overt hepatic encephalopathy. Meanwhile, AXA1125 is progressing through multiple trials: a Phase 2b study targeting non-alcoholic steatohepatitis (NASH) treatment, and a Phase 2a study exploring its efficacy as a therapy for Long COVID patients. Founded in 2008, the entity initially operated as Newco LS16, Inc. before officially adopting the name Axcella Health Inc. in June 2016. Its operations are headquartered in Cambridge, Massachusetts.
Harga Saham
$4.58
Disegerakkan terakhir: 2025-02-06
Perubahan (1 tahun)
0.00%
Perdagangan Axcella Health Inc. (AXLA)
Harga AXLA dengan permodalan pasaran b
Modal pasaran bagi Axcella Health Inc.(AXLA)
Modal Pasaran: $189.73M
Sehingga August 2026, Axcella Health Inc. mempunyai modal pasaran sebanyak $189.73M. Ini menjadikan Axcella Health Inc. syarikat ke-18693rd paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Axcella Health Inc. dari 2019 hingga 2026
AXLA berbanding dengan 5 teratas yang paling popular stocks
| Harga AXLA |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.088T
|
+2,681,511.29%
|
|
|
|
|
$4.629T
|
+2,439,708.64%
|
|
|
|
|
$4.108T
|
+2,165,321.61%
|
|
|
|
|
$3.687T
|
+1,943,019.60%
|
|
|
|
|
$2.800T
|
+1,475,480.92%
|
